Blue Note Therapeutics, a San Francisco, CA-based prescription digital therapeutics company, raised an additional $5.2m, bringing the Series A financing to a total of $31m.
The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
The additional proceeds will strengthen the company’s capacity to develop evidence-based therapeutics.
Led by Geoffrey Eich, CEO, Blue Note Therapeutics is singularly dedicated to patients suffering from cancer. Working closely with cancer research and patient communities, the company is developing a pipeline of clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other forms of cancer-related distress.